爱朋医疗在无创脑科学领域布局了多模态ADHD行为治疗管理系统，该产品覆盖了从院内的行为训练中 心到院外家庭训练场景之间的数据互联，采用科学脑电监测、多模态干预训练等方式，帮助儿童逐步改 善多动及注意缺陷行为，提升专注力。 在脑电技术和脑状态前沿研究方面，公司拥有麻醉深度监测仪产品，在以麻醉深度监测为代表的围术期 监测、诊断、预警应用方面有较深的技术储备。同时，公司正在预研开发癫痫预警平台，未来将全力推 进围术期脑状态监测、多动症、睡眠疾病诊治、癫痫等精神类疾病诊疗的临床创新应用。 中证报中证网讯(记者孟培嘉)爱朋医疗（300753）在10月15日披露的投资者关系活动记录表中表示，公 司主营医疗器械，致力于急慢性疼痛管理、鼻腔及上气道管理两大细分领域，并积极开拓脑机接口创新 业务。 "公司脑机接口医疗应用领域的业务布局包括围术期脑状态监测、顽固性失眠麻醉治疗系统、多模式 ADHD行为治疗管理系统等，同时参股了神经调控领域的瑞神安医疗。"爱朋医疗相关负责人表示。 在侵入式脑机接口领域，公司外延式布局了常州瑞神安，其主要从事脑神经调控及颅内植入电极等医疗 器械产品的研发、生产及销售。 ...

证券代码：300753 证券简称：爱朋医疗 江苏爱朋医疗科技股份有限公司 投资者关系活动记录表 编号：2025-005 | | 特定对象调研 | | | | 分析师会议 | | --- | --- | --- | --- | --- | --- | | 投资者关系活动 | 媒体采访 | | | | 业绩说明会 | | 类别 | 新闻发布会 | | | | 路演活动 | | | 现场参观 | | | | | | | 其他（电话会议） | | | | | | 参与单位名称及 | 信达证券胡琎心，信达证券王哲毓，南方基金王艺文，平安基金李清 斌，中银基金赵建忠，前海开源基金张安华，长盛基金洪靖怡，国联 | | | | | | 人员姓名 | 基金杜伟，中信资管魏巍，中信资管唐天，华夏久盈资管于海申，上 | | | | | | | 海东方证券资管江琦，太平资产管理赵洋等 人 13 | | | | | | 时间 | 2025 年 月 日 | 10 | 15 | 10:00-11:00 | | | 地点 | 网络电话会议 | | | | | | 上市公司接待人 | 董事会秘书叶俞飞先生，证券事务代表黄秀秀女 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is experiencing rapid development and has promising commercial prospects, with a focus on diverse technical paths and applications in the medical field [5][6][32] - The BCI technology is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages in signal quality, safety, and operational difficulty [18][20] - The core technological barriers of BCI are concentrated in the upstream of the industry chain, including hardware (electrodes, chips), surgical procedures, and signal processing [25][28] Summary by Sections 1. BCI Development and Applications - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to facilitate communication between the brain and external devices [15] - The medical application of BCI is predominant, accounting for 56% of the market in 2023, with potential in diagnosing and treating cognitive disorders, mental illnesses, and motor disabilities [33][36] 2. BCI Policy and Pricing - The National Healthcare Security Administration has established a pricing standard for BCI services, addressing the slow commercialization of BCI technology and creating a pricing framework that covers the entire service chain [40][42] 3. BCI Companies and Market Trends - Non-invasive BCI products are leading in commercialization, while invasive and semi-invasive products are still in clinical research stages [43] - Key companies in the BCI space include NeuroPace, BrainGate, Neuralink, and Paradromics, each focusing on various applications such as epilepsy treatment and motor function recovery [43]